Anti-PAD4 antibody
AssigneesPublic University Corporation Yokohama City University, Public University Corporation Nagoya City University, Pharma Foods International Co., Ltd.
InventorsMamoru Sato, Michiyuki Yamada, Satoshi Kanazawa, Masayoshi Toyoura, Yuji Shoya, Kenji Saito, Chihiro Yamazaki
Life of this patent
Estimating the term…
Abstract
Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.
Claims21
An anti-PAD4 (peptidylarginine deiminase 4) monoclonal antibody which specifically binds to positions 345, 347, and 348 of human PAD4, and wherein said antibody inhibits citrullination activity of PAD4 and binds human PAD4 with a KD (M) of 9.0×10−9 or less.
An anti-PAD4 antibody comprising:
- heavy chain CDRs 1 to 3 and light chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 50 to 55, respectively;
- heavy chain CDRs 1 to 3 and light chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 56 to 61, respectively;
- heavy chain CDRs 1 to 3 and light chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 62 to 67, respectively;
- heavy chain CDRs 1 to 3 and light chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 68 to 73, respectively;
- heavy chain CDRs 1 to 3 and light chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 74 to 79, respectively;
- or
- heavy chain CDRs 1 to 3 and light chain CDRs 1 to 3 comprising amino acid sequences set forth in SEQ ID NOs:
- 80 to 85, respectively.
Dependencies are inferred from the claim text.